See more : HomeCo Daily Needs REIT (HDN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of H. Lundbeck A/S (HLUBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of H. Lundbeck A/S, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Rexel S.A. (RXEEY) Income Statement Analysis – Financial Results
- Sonec Corporation (1768.T) Income Statement Analysis – Financial Results
- Unique Fabricating, Inc. (UFABQ) Income Statement Analysis – Financial Results
- First Au Limited (FRSAF) Income Statement Analysis – Financial Results
- Erste Group Bank AG (EBO.DE) Income Statement Analysis – Financial Results
H. Lundbeck A/S (HLUBF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lundbeck.com
About H. Lundbeck A/S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.91B | 18.25B | 16.30B | 17.67B | 17.36B | 17.88B | 17.23B | 15.63B | 14.59B | 13.47B | 15.26B | 14.80B | 16.01B | 14.77B | 13.75B | 11.28B | 10.98B | 9.22B | 9.07B | 9.73B |
| Cost of Revenue | 4.49B | 3.95B | 3.65B | 4.17B | 3.39B | 3.46B | 3.88B | 4.08B | 5.40B | 4.16B | 4.04B | 3.33B | 3.17B | 2.96B | 2.66B | 1.84B | 2.20B | 1.65B | 1.49B | 932.90M |
| Gross Profit | 15.43B | 14.30B | 12.65B | 13.50B | 13.97B | 14.42B | 13.35B | 11.55B | 9.20B | 9.31B | 11.22B | 11.48B | 12.84B | 11.81B | 11.09B | 9.44B | 8.79B | 7.58B | 7.58B | 8.80B |
| Gross Profit Ratio | 77.48% | 78.35% | 77.62% | 76.42% | 80.50% | 80.67% | 77.48% | 73.89% | 63.03% | 69.11% | 73.54% | 77.54% | 80.22% | 79.97% | 80.69% | 83.72% | 79.99% | 82.15% | 83.60% | 90.41% |
| Research & Development | 3.46B | 3.75B | 3.82B | 4.55B | 3.12B | 3.28B | 2.71B | 2.97B | 8.15B | 2.80B | 2.87B | 2.92B | 3.32B | 3.05B | 3.20B | 2.99B | 2.19B | 1.96B | 1.78B | 1.04B |
| General & Administrative | 1.29B | 1.08B | 933.00M | 966.00M | 899.00M | 762.00M | 833.00M | 805.00M | 1.16B | 1.54B | 2.55B | 1.64B | 2.11B | 1.91B | 1.86B | 1.65B | 1.51B | 1.42B | 1.30B | -815.80M |
| Selling & Marketing | 7.48B | 6.61B | 5.89B | 5.95B | 5.51B | 5.28B | 5.65B | 5.49B | 6.71B | 4.87B | 4.20B | 5.27B | 4.02B | 3.50B | 3.17B | 2.46B | 2.41B | 2.42B | 2.34B | 1.44B |
| SG&A | 8.78B | 7.69B | 6.82B | 6.91B | 6.41B | 6.04B | 6.48B | 6.29B | 7.87B | 6.41B | 6.75B | 6.92B | 6.13B | 5.41B | 5.04B | 4.11B | 3.92B | 3.84B | 3.64B | 628.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 95.80M |
| Operating Expenses | 12.23B | 11.44B | 10.64B | 11.52B | 10.04B | 9.36B | 9.19B | 9.26B | 16.02B | 9.21B | 9.62B | 9.83B | 9.45B | 8.45B | 8.23B | 7.70B | 6.48B | 6.11B | 5.75B | 6.25B |
| Cost & Expenses | 16.72B | 15.39B | 14.29B | 15.68B | 13.43B | 12.82B | 13.07B | 13.34B | 21.41B | 13.37B | 13.66B | 13.16B | 12.61B | 11.41B | 10.89B | 9.54B | 8.68B | 7.75B | 7.24B | 7.18B |
| Interest Income | 43.00M | 22.00M | 7.00M | 6.00M | 39.00M | 29.00M | 183.00M | 172.00M | 288.00M | 310.00M | 154.00M | 13.00M | 116.00M | 137.00M | 370.00M | 419.40M | 337.10M | 250.10M | 458.50M | 82.70M |
| Interest Expense | 54.00M | 103.00M | 153.00M | 181.00M | 24.00M | 4.00M | 314.00M | 307.00M | 478.00M | 465.00M | 281.00M | 85.00M | 212.00M | 205.00M | 178.00M | 407.00M | -387.00M | -313.90M | -296.20M | 23.00M |
| Depreciation & Amortization | 2.01B | 1.81B | 1.71B | 2.79B | 1.67B | 1.18B | 1.25B | 1.34B | 7.03B | 310.00M | 154.00M | 888.00M | 116.00M | 1.04B | 870.00M | -604.80M | -387.00M | -313.90M | -336.60M | 617.70M |
| EBITDA | 5.06B | 4.59B | 3.64B | 4.88B | 4.76B | 6.46B | 5.42B | 3.64B | 498.00M | 1.86B | 1.75B | 2.55B | 4.62B | 4.53B | 3.71B | 1.75B | 2.31B | 1.47B | 1.85B | 3.15B |
| EBITDA Ratio | 25.41% | 25.17% | 22.30% | 27.12% | 22.19% | 27.02% | 25.24% | 25.70% | 3.41% | 3.04% | 11.49% | 17.21% | 21.92% | 30.68% | 27.02% | 15.48% | 21.01% | 15.94% | 20.21% | 32.39% |
| Operating Income | 3.20B | 2.85B | 2.01B | 1.99B | 3.61B | 5.30B | 4.41B | 2.29B | -6.82B | 99.00M | 1.60B | 1.65B | 3.39B | 3.36B | 2.86B | 2.35B | 2.70B | 1.78B | 2.17B | 2.55B |
| Operating Income Ratio | 16.05% | 15.63% | 12.33% | 11.26% | 20.79% | 29.66% | 25.58% | 14.66% | -46.70% | 0.74% | 10.48% | 11.13% | 21.20% | 22.74% | 20.79% | 20.84% | 24.54% | 19.35% | 23.92% | 26.24% |
| Total Other Income/Expenses | -202.00M | -378.00M | -429.00M | -84.00M | -127.00M | -12.00M | -131.00M | -135.00M | -190.00M | -155.00M | -127.00M | 14.00M | -96.00M | -68.00M | -192.00M | -71.00M | -133.90M | -151.20M | 72.30M | -32.40M |
| Income Before Tax | 2.99B | 2.47B | 1.58B | 1.91B | 3.48B | 5.29B | 4.28B | 2.16B | -7.01B | -56.00M | 1.47B | 1.58B | 3.30B | 3.29B | 2.67B | 2.12B | 2.56B | 1.63B | 2.26B | 2.52B |
| Income Before Tax Ratio | 15.03% | 13.56% | 9.70% | 10.79% | 20.05% | 29.59% | 24.82% | 13.80% | -48.01% | -0.42% | 9.65% | 10.69% | 20.60% | 22.28% | 19.39% | 18.82% | 23.32% | 17.71% | 24.87% | 25.90% |
| Income Tax Expense | 703.00M | 558.00M | 263.00M | 325.00M | 814.00M | 1.38B | 1.65B | 946.00M | -1.31B | 97.00M | 617.00M | 475.00M | 1.02B | 823.00M | 659.00M | -613.30M | -792.00M | -525.90M | -667.40M | 832.30M |
| Net Income | 2.29B | 1.92B | 1.32B | 1.58B | 2.31B | 3.91B | 2.62B | 1.21B | -5.69B | -153.00M | 855.00M | 1.17B | 2.28B | 2.47B | 2.01B | 1.66B | 1.77B | 1.11B | 1.57B | 1.71B |
| Net Income Ratio | 11.50% | 10.50% | 8.09% | 8.95% | 13.33% | 21.86% | 15.23% | 7.75% | -39.02% | -1.14% | 5.60% | 7.87% | 14.26% | 16.70% | 14.60% | 14.74% | 16.11% | 12.00% | 17.36% | 17.56% |
| EPS | 2.31 | 1.93 | 1.33 | 7.96 | 11.64 | 19.67 | 13.28 | 6.14 | -28.98 | -0.78 | 4.36 | 5.94 | 11.63 | 12.57 | 10.24 | 8.45 | 8.63 | 5.24 | 7.05 | 7.44 |
| EPS Diluted | 2.31 | 1.93 | 1.33 | 7.96 | 11.64 | 19.66 | 13.26 | 6.13 | -28.95 | -0.78 | 4.36 | 5.94 | 11.63 | 12.57 | 10.24 | 8.45 | 8.63 | 5.23 | 7.03 | 7.43 |
| Weighted Avg Shares Out | 992.24M | 992.87M | 993.31M | 198.73M | 198.69M | 198.68M | 197.51M | 197.19M | 196.47M | 196.25M | 196.14M | 196.13M | 196.10M | 196.12M | 196.12M | 196.84M | 204.99M | 211.10M | 224.56M | 229.61M |
| Weighted Avg Shares Out (Dil) | 992.24M | 992.87M | 993.31M | 198.73M | 198.72M | 198.74M | 197.79M | 197.41M | 196.71M | 196.39M | 196.18M | 196.14M | 196.10M | 196.12M | 196.12M | 196.84M | 204.99M | 211.10M | 225.07M | 229.83M |
Source: https://incomestatements.info
Category: Stock Reports